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Heparan sulfate mimetica b s t r a c t
Parkinson’s disease (PD) is characterized by progressive degeneration of dopaminergic nigrostriatal neu-
rons and reduction in striatal dopamine levels. Although there are few treatment options for PD such as
Levodopa, they are used just to relieve and modify the symptoms. There are no therapies available for PD
to slow down the degeneration process in the brain and recover the lost function. In this study, we used
extracellular matrix (ECM) mimetic peptide amphiphile (PA) nanofibers as a potential therapeutic
approach in a PD rat model. We demonstrated the effect of heparan sulfate mimetic and laminin mimetic
PA nanofibers on reducing striatal injury and enhancing functional recovery after unilateral striatal injec-
tion of 6-hydroxydopamine (6-OHDA). The bioactive self-assembled PA nanofibers significantly reduced
forelimb asymmetry, contralateral forelimb akinesia and d-amphetamine-induced rotational behavior in
cylinder, stepping and rotation tests, respectively, in 6-OHDA-lesioned rats after 6 weeks. The behavioral
improvement with PA nanofiber administration was associated with enhanced striatal dopamine and tyr-
osine hydroxylase content as well as reduced cleaved-Caspase-3 levels. Histological assessment also
showed that PA nanofiber injection to the striatum resulted in better tissue integrity compared to control
groups. In addition, PA nanofibers reduced the progressive cell loss in SH-SY5Y cells caused by 6-OHDA
treatment. These data showed that the bioactive peptide nanofibers improve neurochemical and behav-
ioral consequences of Parkinsonism in rats and provide a promising new strategy for treatment of PD.
Statement of Significance
Biomimetic nanomaterials bearing natural bioactive signals which are derived from extracellular matrix
components like laminin and heparan sulfates provide promising therapeutic strategies for regeneration
of the nervous system. However, no research has been reported exploring the use of biomimetic materials
against degeneration in Parkinson’s disease. In this work, we investigated potential therapeutic effects of
heparan sulfate and laminin mimetic PA nanofibers on reduction of striatal injury in experimental
Parkinson’s disease model. PA nanofibers enhanced functional recovery associated with enhanced striatal
dopamine and tyrosine hydroxylase content as well as reduced cleaved-Caspase-3 levels. Overall, this
study shows the improvement in consequences of Parkinsonism in rats and provides a new platform
for treatment of Parkinson’s disease.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.1. IntroductionNeurodegenerative diseases caused by infection, stroke and
acute trauma are the fourth cause of death in theworld after cardio-
vascular diseases, cancer and stroke [1]. Among the neurodegenera-
tive diseases, Parkinson’s disease (PD) is the second most common
neurodegenerative disease after Alzheimer’s disease. PD is a severe,
chronic and progressive disease associated with symptoms such as
tremor, postural instability, rigidity and bradykinesia [2]. PD is char-
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quence of dopaminergic neuron loss in the substantia nigra pars
compacta. Beside the degeneration of dopaminergic neurons, Lewy
body formation can be included into pathologic hallmarks of PD
[3]. In addition, several studies have shown that activation of apop-
tosis is oneof themechanisms thatunderlie progressive striatal neu-
rodegeneration [4–7]. Also, a recent study has provided strong
evidence for this hypothesis by showing that in vivo suppression of
Caspase-3, an apoptotic marker, by RNA interference in a rat model
of PD reduced striatal dopaminergic cell loss and improved locomo-
tor activity [8]. Millions of people in US and Europe suffer from PD,
but thepharmaceutical agentsused for PD treatment including levo-
dopa, Monoamine oxidase-B inhibitors (selegiline and rasagiline),
Catechol-O-methyl transferase inhibitors (tolcapone and enta-
capone) and dopamine agonists (pramipexole and ropinirole) just
relieve andmodify the symptoms. In addition, since they are admin-
istered orally, they can cause systemic toxicity with different
adverse effects [9]. There are no therapies yet available for PD to
slowdown thedegenerationprocess in thebrain and recover the lost
function. Besides these current strategies, there are various experi-
mental approaches to improve the efficacy of currently available
treatment strategies. Uses of adenosine A2A receptor antagonists,
glutamate receptor antagonists, monoamine oxidase inhibitors,
anti-apoptotic agents, antioxidants and coenzyme Q10 are among
the emerging pharmacotherapies at different stages of preclinical
and clinical trials [10]. Also, there are several non-pharmacological
approaches offering alternative strategies for the treatment of PD.
Viral vectors were studied to silence the over-expressed defective
genes considered as risk factors in PD or to transfer the genes such
as glutamic acid decarboxylase gene [11]. Stem cell transplantation
is another promising approach for the replacement of dopaminergic
neurons progressively lost in PD. Induced pluripotent stem cells,
neural stem cells and mesenchymal stem cells are the most com-
monly studied resources to generate dopaminergic neurons as a
treatment strategy for PD [12]. However, there are some drawbacks
for this technique such as selecting tumor-free cell type for trans-
plantation, which limits the potential therapeutic benefits. Addi-
tionally, some surgical procedures are within the emerging
techniques for PD treatment, including deep brain stimulation, pal-
lidotomy and thalamotomy, especially for PD patients having severe
disabling problems and not responding traditional treatment
options. However, these procedures also have high risks and require
close post-operative follow-up period [10].
Although repairing the damaged area in the brain is extremely
challenging, recent advances in regenerative medicine and tissue
engineering provide new therapeutic approaches for neurodegen-
erative disease treatment. Biomaterials, which are designed to
interact with biological systems provide new platforms to replace
the damaged neurons or slow down the progression of the diseases
[13]. Biomaterial scaffolds can be modified with physical or/and
chemical cues depending on aim of the study. Cell attachment,
adhesion, migration and spreading as well as cell differentiation
into specific lineages can be achieved through physical or chemical
modification of the surface of the scaffold, including stiffness,
topography, charge and interactions with extracellular-matrix
(ECM) proteins or cells [14].
Laminins are heterotrimeric proteins and the major non-
collagenous components of the basal lamina. They bind to cellmem-
brane through interactionwith integrin receptors on the cell surface,
and by this way they can influence diverse biological activities
including the adhesion, migration and differentiation [15]. More-
over, laminin has a fundamental role in axonal growth andmyelina-
tion [16] and functions as a neurite-outgrowth promoting factor for
peripheral and central neurons [17]. Laminin also interacts with
other matrix elements such as heparan sulfate proteoglycans
(HSPG) through noncovalent interactions, and laminin-HSPG com-plexwas found tobe involved inneurite outgrowth [18,19]. Heparan
sulfates are highly sulfated glycosaminoglycans and function as
cell–ECM interface to modify cell signaling. They also interact with
various ECM molecules such as growth factors. They act as a reser-
voir of such growth factors and increase their local concentration
[20–23].
The self-assembled peptide amphiphile (PA) nanofibers provide
suitable platforms tomimic ECM.As a result of hydrophobic interac-
tion of alkyl tails and b-sheet formation between PAmolecules, they
self-assemble into nanofibers in aqueous environment. Also, bio-
chemical signals provided by a specific protein can be introduced
into the nanofiber system through addition of bioactive epitopes
into individual PA molecules instead of use of bulk protein [24].
The peptide sequences Ile-Lys-Val-Ala-Val (IKVAV) of cell-binding
domain of laminin was discovered and found to facilitate neurite
extension [25]. After the discovery of this small peptide sequence,
IKVAV-carrying PAs were used in both in vitro and in vivo studies
for neural differentiation [26] and spinal cord regeneration
[27,28], respectively. We previously reported that combination of
IKVAV-carrying PAs along with heparan-sulfate-mimicking PA
nanofibers displayed dual bioactivity and promoted much longer
neurite outgrowth compared to the scaffold with laminin-derived
signals alone, even in the presence of inhibitory conditions provided
by chondroitin sulfate proteoglycans [29]. Although bioactive PA
nanofibers were shown to enhance in vitro neurite extension or
peripheral nerve regeneration, there is no study on the therapeutic
effects of bioactive PA nanofibers on Parkinson’s disease.
Here we investigated whether these heparan sulfate and
laminin mimetic PA nanofibers have potential therapeutic effect
for both protection of SH-SY5Y cells against 6-hydroxydopamine
(6-OHDA)-induced apoptosis in in vitro studies and for reducing
striatal injury and enhancing dopaminergic nerve regeneration in
experimental PD model. Six weeks following treatment with
bioactive PA nanofibers, rats with 6-OHDA-induced Parkinsonism
displayed improvements in behavioral functions, i.e., reductions
in forelimb asymmetry, contralateral forelimb akinesia and
d-amphetamine-induced rotational behavior in cylinder, stepping
and rotation tests, respectively. Moreover, brain dopamine content
and tyrosine hydroxylase (TH) levels increased, while cleaved-
Caspase-3 levels decreased in rats treated with PA nanofibers com-
pared to sucrose control. Histological assessment also showed that
PA injection to the striatum provided better tissue integrity by
reducing the progressive cell loss caused by 6-OHDA toxicity,
which makes this bioactive nanofiber system a promising new
platform for PD treatment.2. Materials and methods
2.1. Materials
All protected amino acids, lauric acid, 4-[a-(20,40-dimethoxyphe
nyl) Fmoc-aminomethylphenoxyacetomidonorleucyl-MBHA resin
(Rink amideMBHA resin), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetrame
thyluroniumhexafluorophosphate (HBTU) and diisopropylethy-
lamine (DIEA) were purchased from Nova-Biochem, ABCR, or
Sigma-Aldrich. 6-OHDAwas purchased from Sigma Aldrich. Alamar
Blue, viability assay reagents and other cell culture materials were
purchased from Invitrogen. Apoptosis assay reagents were pur-
chased from Biotium. All other chemicals andmaterials used in this
study were purchased from Thermo Scientific or Sigma Aldrich.2.2. Synthesis of PA molecules
PA molecules were synthesized on Rink Amide MBHA Resin or
Fmoc-Glu(OtBu)-Wang Resin by using Fmoc-protected solid phase
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with 2 equivalents of aminoacids activated with 1.95 equivalents
of HBTU and 3 equivalents of DIEA for 2 h. Fmoc removal was per-
formed with 20% piperidine–dimethylformamide (DMF) solution
for 20 min. 10% acetic anhydride–DMF solution was used to per-
manently acetylate the unreacted amine groups after each cou-
pling step. DMF and dichloromethane (DCM) were used as
washing solvents after each step. p-Sulfobenzoic acid was coupled
to the side chain of lysine to synthesize sulfonated PAs. A lysine
residue with 4-methytrityl (Mtt) side chain protection was used
for selective deprotection of amine groups. Mtt removal was per-
formed by shaking resins for 5 min with TFA:TIS:H2O:DCM in the
ratio of 5:2.5:2.5:90. Cleavage of the PAs and protection groups
from the resin was carried out with a mixture of TFA:TIS:H2O in
the ratio of 95:2.5:2.5 for 3 h. Excess TFA removal was carried
out by rotary evaporation. PAs in the remaining solution were pre-
cipitated in ice-cold diethyl ether overnight. The precipitate was
collected by centrifugation next day and dissolved in ultrapure
water. This solution was frozen at -80 C for 4 h and then lyophi-
lized for 4–5 days. PAs were characterized by liquid chromatogra-
phy–mass spectrometry (LC–MS). Mass spectrum was obtained
with Agilent LC-MS equipped with Agilent 6530 Q-TOF with an
ESI source and Zorbax Extend-C18 2.1  50 mm column for basic
conditions and Zorbax SB-C8 4.6  100 mm column for acidic con-
ditions. A gradient of (a) water (0.1% formic acid or 0.1% NH4OH)
and (b) acetonitrile (0.1% formic acid or 0.1% NH4OH) was used.
In order to remove residual TFA, positively-charged PAs were trea-
ted with 0.1 M HCl solution and lyophilized. To purify the peptides,
Agilent preparative reverse-phase HPLC system equipped with Zor-
bax Extend-C18 21.2  150 mm column was used for basic condi-
tions and Zorbax SB-C8 21.2  150 mm column was used for acidic
conditions. A gradient of (a) water (0.1% TFA or 0.1% NH4OH) and
(b) acetonitrile (0.1% TFA or 0.1% NH4OH) was used. All peptide
batches were freeze-dried and reconstituted in ultrapure water
at pH 7.4 before use.
2.3. Physical, mechanical and chemical characterization of self-
assembled nanofiber network
2.3.1. Scanning electron microscopy (SEM)
PA nanofiber networks were observed by imaging with a scan-
ning electron microscope (SEM). Oppositely charged PA solutions
(1 wt%) were mixed in appropriate volume ratio (final volume
being 30 lL) to produce gels with neutral charge. Gels were formed
on silicon wafer and dehydrated by transferring to 20%, 40%, 60%,
80% and 100% v/v ethanol sequentially. They were critical point-
dried afterwards by using Autosamdri 815B equipment from Tou-
simis. Dried PA gels were coated with 4 nm Au/Pd and SEM (FEI
Quanta 200 FEG) images were taken by using an Everhart–Thorn-
ley Detector (ETD) at high vacuum mode at 5 keV beam energy
2.3.2. Scanning transmission electron microscope (STEM)
Samples for STEM imaging were prepared by mixing equal vol-
umes of negatively and positively charged PA molecules with
appropriate concentrations for charge neutralization and placing
them on a 200-mesh carbon TEM grid for 10 min followed by
2 wt% uranyl acetate staining for 2 min and drying. STEM images
at HAADF mode were acquired with FEI Tecnai G2 F30 TEM at
300 kV.
2.3.3. Circular dichroism (CD)
A JASCO J815 CD spectrometer was used at room temperature.
Oppositely charged 2.5  104 M PA solutions were mixed in
appropriate volume ratios (final volume being 500 lL) to produce
nanofibers with net neutral charge. Measurements were carried
out from 300 nm to 190 nm; data interval and data pitch being0.1 nm, and scanning speed being 100 nmmin1. All measure-
ments were performed with three accumulations. Digital Integra-
tion Time (DIT) was selected as 1 s, band width as 1 nm, and the
sensitivity was standard.
2.3.4. Oscillatory rheology
Oscillatory rheology measurements were performed with
Anton Paar Physica RM301 Rheometer operating with a 25 mm
parallel plate configuration at 25 C. 250 lL total volume with
1 wt% of each PA component was carefully loaded onto the center
of the lower plate and incubated for 10 min for gelation before
measurement. After equilibration, the upper plate was lowered
to a gap distance of 0.5 mm. Storage moduli (G0) and loss moduli
(G00) values were scanned from 100 rad s1 to 0.1 rad s1 of angular
frequency, with a 0.5% shear strain. Three samples were measured
for each PA gel.
2.4. Cell culture and maintenance
SH-SY5Y cells (kindly provided by Prof. Dr. Fikrettin Sahin,
Yeditepe University, Istanbul, Turkey) were used in cell culture
experiments. They were cultured in 75 cm2 flasks at 37 C in a
humidified incubator and supplied with 5% CO2. Cells were main-
tained in 1:1 mixture of Eagle’s minimum essential medium and
F12 medium supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin. All cell experiments were carried
out after reaching 90% confluency. The culture medium was
changed every 3–4 days.
2.5. Drug treatment and viability assay
6-OHDA was dissolved in 0.3% L-ascorbic acid/0.9% NaCl solu-
tion to create a stock concentration of 5 mM and was used at a final
concentration of 25, 50, 100, 200 and 500 lM. SH-SY5Y cells were
seeded at a density of 2  104 cells/well on 96-well plate and incu-
bated for 24 h. Then, they were treated with 6-OHDA (25, 50, 100,
200 and 500 lM) for 24 h. Medium was discarded after 24 h of
incubation and replaced with medium containing 10% Alamar blue.
Blank group contained only Alamar blue medium without cells.
After 3 h incubation at 37 C, absorbance measurement was per-
formed by using Spectramax M5 microplate reader at 570 and
600 nm as reference.
After determining the toxic dose, the viability test of SH-SY5Y
cells was performed after 24 h of 6-OHDA treatment by using
calcein-AM/ethidium homodimer 1 (EthD-1) staining. In brief, cells
were incubated on PA-coated and uncoated 96 well-tissue culture
plates at a density of 5  103 cells/well. After 24 h, the cells were
exposed to 50 lM 6-OHDA dissolved in 0.3% L-ascorbic acid/saline
solution or vehicle (0.3% L-ascorbic acid/saline solution). After 24 h
of incubation, cell medium was discarded; cells were washed with
PBS and then incubated with 2 lM calcein-AM and 2 lM EthD-1 in
PBS for 30 min at room temperature. Finally, five random images
were taken at 100x magnification from each well for both
qualitative and quantitative analysis by using Zeiss Axioscope
fluorescence microscope. Cells were counted with Image J system
for analyzing proliferation.
2.6. Flow cytometric analysis of apoptosis
Apoptosis in SH-SY5Y cells seeded on different PA combinations
was measured using the Annexin V-FITC Apoptosis Detection kit.
After 24 h incubation in 6-well plates at a density of 5  105
cells/well, the cells were exposed to 50 lM 6-OHDA dissolved in
0.3% L-ascorbic acid/saline solution. After 24 h exposure to 6-
OHDA, flow cytometry protocol for Annexin V and propidium
iodide was performed. Medium was discarded; cells were washed
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100 lL of 1X annexin-binding buffer per assay was added with
5 lL Alexa Fluor 488 annexin V and 1 lL of 100 lg/mL propidium
iodide. Cells were incubated at room temperature for 15 min. The
stained cells were analyzed by flow cytometry, measuring the flu-
orescence emission at 530 nm (e.g., FL1) and >575 nm (e.g., FL3).
2.7. In vivo surgery
2.7.1. Animals
A total of 32 male Sprague Dawley rats (weighing 300–350 g)
were housed individually in each cage with free access to food
and water in a 12/12 h light/dark cycle. Experimental procedures
conformed to the National Institute of Health Guide for the Care
and Use of Laboratory Animals and were approved by the Local
Ethics Committee on Experimental Animal Research of Uludag
University, Bursa, Turkey (Approval ID: 2012-10/1).
2.7.2. Surgical procedures
Rats (n = 24) anesthetized with ketamine and xylazine (80 and
10 mg/kg, respectively) were placed into the stereotaxic apparatus
(David Kopf Instruments, Tujunga, CA, USA). Their heads were
shaved and a 2-cm incision was made on the skull under aseptic
conditions ensured with 70% alcohol. After visualization of the
bregma, two burr holes were drilled and hand-made guide cannu-
las (each 4 mm long) were placed (first one +0.48 mm anterior and
second one -0.40 mm posterior to bregma). The cannulas were
plugged and rats were returned to their cages after injection with
a single dose of analgesic (buprenorphine; 0.05 mg/kg; s.c.). A
group of rats (n = 8) underwent the same operation without place-
ment of guide cannulas in order to serve as sham controls.
2.7.3. Intrastriatal lesioning with 6-OHDA and PA injection
24 h after the placement of guide cannulas, two injection appa-
ratus were placed into the right striata of rats through the guide
cannulas at the following coordinates: first at anteroposterior:
+0.48 mm, mediolateral: 2.2 mm and vertical: 4.6 mm and
second at anteroposterior: 0.40 mm, mediolateral: 4.0 mm
and vertical: 6.0 mm according to the Rat Brain Atlas [30].
Freely-moving rats were injected intrastriatally through polyethy-
lene tubing (PE 20; Becton Dickinson, Franklin Lakes, NJ, USA)
attached to the apparatus at the given coordinates with either
8 lg of 6-OHDA (dissolved in saline containing 0.3% L-ascorbic acid,
n = 16) or its solvent 0.3% L-ascorbic Acid (n = 8) at a volume of 2 lL
using an injection pump with a flow rate of 1 lL/min. The cannulas
were plugged and rats were followed up in individual cages with
free access to food and water.
The dose and stereotaxic coordinates for 6-OHDA injections
were selected from previous studies [31,32] which showed that
this protocol is adequate for consistent depletion of approximately
70–80% of striatal dopamine and induce Parkinsonism in rats
resembling the early phase of PD in clinical setting.
One week later, rats receiving intrastriatal 6-OHDA injections
were tested for d-amphetamine-induced rotational behavior. Rats
were injected intraperitoneally (i.p.) with d-amphetamine (5 mg/
kg) and ipsilateral rotations between 15 and 45 min were recorded
using an automated Rotameter system (TSE Systems, Germany).
Initial behavioral task was performed in order to ensure that the
unilateral striatal 6-OHDA lesion was established and the data
were used to randomize the 6-OHDA-lesioned rats into two treat-
ment groups (i.e., 6-OHDA + Sucrose [n = 8] and 6-OHDA + PA
[n = 8] groups) with almost equal mean number of ipsilateral rota-
tions (275 ± 11 and 275 ± 6, respectively) in this task. No rotational
behavior was observed in rats in ‘‘Sham” and ‘‘L-Ascorbic Acid + PA”
groups.Rats were followed-up in their cages for three days after the
initial rotational behavior task in order to allow for wash-out of
d-amphetamine from the brain and then allocated into treatment
groups as follows: (i) Sham group, (ii) L-Ascorbic Acid + PA group,
(iii) 6-OHDA + Sucrose group and, (iv) 6-OHDA + PA group.
Schematic representation of the experimental protocol has been
presented in Fig. S2.
In rats receiving intrastriatal 6-OHDA or L-ascorbic acid injec-
tions, PA (1% aqueous solutions) or sucrose (0.25 M) injections
were made using the same coordinates of the right striata through
the existing guide cannulas. The 1% solutions dissolved in sucrose
of both the heparan sulfate-mimicking (GAG) and laminin-derived
(LN) PA nanofibers were injected consecutively by the help of the
polyethylene tubing attached to the injection apparatus with a
5 min interval in between two injections. In vivo gel formation
and further cell recruitment by LN-PA and GAG-PA were verified
with preliminary studies (Fig. S3). After preliminary studies, same
protocol was applied, and rats were then followed-up for a period
of 6 weeks in individual cages with free access to food and water.
2.8. Behavioral analyses
2.8.1. Rotation test
On completion of 6 weeks, rats were subjected to rotational test
as described above.
2.8.2. Cylinder test
Cylinder test was performed in order to evaluate the forelimb
asymmetry in rats using a modified version [33] of the initially-
described procedure [34]. Briefly, rats were put individually in a
glass cylinder (21 cm diameter, 34 cm height) and video recorded
for 5 min without prior habituation. To stimulate rats that showed
little or no tendency to explore, the following methods were used
in the given order: (i) turning the lights in the room on and off 2 ± 3
times; (ii) mildly shaking the cylinder for 2 ± 3 s; (iii) taking the rat
out of the cylinder for approximately 30 s and then putting it back,
as described previously [35]. Ipsilateral or contralateral forelimb
touches to the cylinder wall were counted by a blinded observer
from the video recordings.
2.8.3. Stepping test
Stepping test (Adjusting Steps Test) was performed in order to
evaluate forelimb akinesia three times on the same day with
30 min intervals in between tests according to the procedure
described previously [36]. Briefly, rats were held by the experi-
menter with one hand fixing the hindlimbs and slightly raising
the hind part above the surface of a table with a width of
100 cm. The other hand fixed the forelimb not to be monitored.
The rats were moved sideways with one paw touching the table
at a speed of 100 cm/5 s first in the forehand and then in the back-
hand direction. The number of adjusting steps was counted for
both paws in both directions by a blinded observer from the video
recordings.
2.9. Animal perfusions and tissue acquisition
Three days after the behavioral tests to allow for the wash-out
of d-amphetamine, rats in all groups were sacrificed either with or
without transcardiac perfusion using 4% paraformaldehyde solu-
tion under ketamine and xylazine anesthesia. Brains were obtained
and striata were excised in rats sacrificed without perfusion.
Striata were homogenized using 0.4 N hydrochloric acid (HCl),
and homogenates were kept for future analyses of dopamine, TH
and cleaved-Caspase-3. Brains of rats obtained following
paraformaldehyde perfusion were sectioned and processed for
immunohistochemical analyses.
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Sections were deparaffinized in xylene and rehydrated in serial
ethanol series for hematoxylin & eosin (H&E) staining according to
the standard protocol. For immunohistochemistry experiments,
sections were stained with anti-TH (1:250; Millipore AB152) and
anti-Iba1 (1:2000 Sigma ab178846) antibodies. After primary anti-
body staining, horseradish peroxidase conjugated goat anti-rabbit
secondary antibody (1:500; Millipore) was used followed by 3,30-
diaminobenzidine (DAB) staining. All samples were mounted onto
glass slides using xylene based mounting medium. Digital images
were acquired via Zeiss Axio Scope A1. Images were acquired by
using 10x and 20x objectives.
2.11. Dopamine analyses
Dopamine contents of striata were analyzed using High
Performance Liquid Chromatography (HPLC) coupled with an
electrochemical detector and an analytical column as described
previously [31]. The samples were run at a rate of 1 mL/min using
a mobile phase containing 0.15 M Na2HPO4, 0.5 mM sodium octa-
sulfate and 0.1 mM Na2EDTA dissolved in 10% methanol solution.
2.12. Western blot analyses
Homogenates of striata were mixed with equal volumes of
Laemmli loading buffer and boiled. Equal amounts of protein wereFig. 1. Chemical structures of PA molecules (a). SEM images of LN-PA/GAG-PA (b), LN-PA
the fibrous ECM structure. Scale bars are 3 lm in length. STEM images of all PA nanofibe
100 nm in length.
Fig. 2. Characterization of secondary structure of peptide nanostructures by circular dic
circular dichroism analysis. Mechanical properties of PA gels measured by oscillatory r
formation by all combinations at pH 7.4.loaded and separated using SDS-PAGE (4–20%; Bio-Rad, Hercules,
CA, USA) and then transferred onto polyvinylidene fluoride (PVDF)
membranes (Millipore, Billerica, MA, USA). The remaining binding
sites were blocked with 4% non-fat dry milk (Carnation, Glendale,
CA, USA) in Tris-buffered saline and Tween 20 (TBST). Membranes
were then rinsed in TBST buffer and incubated overnight in TBST
solution containing the primary antibody of interest (rabbit anti-
TH [Millipore, Billerica, MA, USA] and rabbit anti-cleaved-
Caspase-3 [Cell Signaling, Danvers, MA, USA]). Next day, blots were
incubated with the appropriate peroxidase-linked secondary anti-
body followed by visualization of protein-antibody complexes
using the enhanced chemiluminescence system (Millipore, Biller-
ica, MA, USA) and digital images were developed using a Licor C-
Digit blot scanner (LI-COR Biotechnology, Lincoln, NE, USA).
Immunoreactive bands were compared densitometrically using
the blot scanner’s software. Membranes were stripped using a
stripping buffer (Thermo Fisher Scientific, Rockford, IL, USA) and
then incubated with mouse anti-bIII-tubulin (Sigma-Aldrich, St.
Louis, MO, USA) antibody used as the loading control.2.13. Statistical analyses
Statistical analyses were performed using Sigma Plot version
12.0 software. Data were expressed as mean ± standard error of
mean. Comparisons between two groups were made using Stu-
dent’s t test and those between multiple groups were made by
using one way ANOVA followed by post hoc Tukey test and one-/E-PA (c), K-PA/GAG-PA (d) and K-PA/E-PA (e) show nanofiber networks resembling
rs formed at pH 7.4 are given in inner frames of panels b, c, d and e. Scale bars are
hroism (a). All PA combinations were found to have b-sheet secondary structure by
heology (b). Rheology results showed gelation as a result of nanofibrous network
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ison test. A p-value of less than 0.05 was considered significant
(*p < 0.05; **p < 0.01; ***p < 0.001).3. Results
3.1. Characterization of the peptide nanofibers
For both in vitro and in vivo studies, four different PA molecules
were synthesized. All PA molecules had a hydrophobic alkyl tail
composed of lauric acid and a b-sheet forming peptide sequence,
VVAG. Lauryl-VVAGIKVAV-Am (LN-PA) was synthesized as laminin
mimetic PA molecule and Lauryl-VVAGEGDK(pbs)S-Am (GAG-PA)
was developed to mimic heparan sulfates with its sulfonate, hydro-
xyl and carboxylic acid groups incorporated as amino acid side
chains. LN-PA/GAG-PA scaffolds bear two bioactive epitopes to
mimic both laminin and heparan sulfates. The other two PA
molecules used in this study were Lauryl-VVAGE (E-PA) and
Lauryl-VVAGK-Am (K-PA) (Fig. 1a). These two PAs did not have
any bioactive epitope sequences and they were used for gel forma-
tion with oppositely charged PAs to obtain K-PA/GAG-PA and LN-
PA/E-PA nanofibers. K-PA/E-PA nanofibers were used as an
epitope-free gel control. The PA molecules were synthesized by
solid phase peptide synthesis, purified with preparative HPLC
and characterized by LC-MS (Fig. S1). By SEM imaging, it was
revealed that nanofiber networks in PA gels had morphological
similarity to natural ECM that surrounds the cells in tissues
(Fig. 1b, c, d and e). In addition, STEM imaging showed that all
nanofibers were uniform in diameter (10–20 nm) and several
micrometers in length (inner frames of Fig. 1b, c, d and e). We
employed a circular dichroism spectrophotometer and observed
predominant b-sheet structures with a chiral absorbance maxi-
mum at around 200 nm and minimum at around 220 nmFig. 3. Effects of PA nanofibers on SH-SY5Y cell viability after 6-OHDA treatment. Concen
assay (a). Viability of SH-SY5Y cells when cultured on peptide nanofibers in the presenc
livedead assay (b). Cell apoptosis on different PA combinations and TCP after 24 h o
(⁄p < 0.05, ⁄⁄⁄p < 0.001). (For interpretation of the references to colour in this figure lege(Fig. 2a). To study the mechanical properties of PA gels, we used
oscillatory rheology. Rheology results showed all PA combinations
had higher storage modulus (G0) than loss modulus (G00), verifying
the gel formation at physiological pH (Fig. 2b).3.2. In vitro studies
The dose response study was crucial to determine the IC50 value
of the 6-OHDA concentration. Different concentrations of 6-OHDA
(0–750 lM) were applied to SH-SY5Y cells and 6-OHDA-induced
cytotoxicity was evaluated using Alamar blue assay. Viability of
SH-SY5Y cells markedly decreased following 24 h incubation with
an increasing concentration of 6-OHDA (Fig. 3a). A concentration of
50 lM for 6-OHDA was chosen for subsequent experiments since
this concentration adequately decreased cell viability to about
50% (p < 0.001). Cellular viability of SH-SY5Y cells treated with
either 6-OHDA or vehicle was assessed by calcein-AM/ethidium
homodimer 1 staining, by comparison to cells that were cultured
on different PA nanofibers. Results demonstrated that the cell
viability on LN-PA/GAG-PA nanofibers was the highest and signif-
icantly greater than other PA combinations (Fig. 3b). Using Annexin
V and the propidium iodide double-staining system, the Annexin
V/propidium iodide population was considered as normal
healthy cells, while Annexin V+/propidium iodide cells were taken
as a measurement of early apoptosis and Annexin V+/propidium
iodide+ as late apoptosis. After 24 h of incubation of cells seeded
on different PA combinations and tissue culture plate (TCP) with
6-OHDA, results showed that the percentage of live cells in LN-
PA/GAG-PA group was significantly higher than other groups
(p < 0.001) (Fig. 3c). Also, percentage of late apoptotic cells was
lowest in LN-PA/GAG-PA group compared to other groups
(p < 0.001), which showed that LN-PA/GAG-PA combination indi-
cates a potentially favorable outcome for in vivo studies.tration-dependent toxicity of 6-OHDA in SH-SY5Y cells determined by Alamar blue
e or absence of 50 lM 6-OHDA for 24 h analyzed by calcein/ethidium homodimer
f culture was tested by flow cytometry analysis (c). Values represent mean ± SEM
nd, the reader is referred to the web version of this article.)
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functions
In cylinder test, rats in Sham, L-Ascorbic Acid + PA, 6-OHDA
+ Sucrose and 6-OHDA + PA groups made 8.5 ± 2, 8.3 ± 1, 7.8 ± 1
and 7.8 ± 1 touches with only the ipsilateral forelimb, respectively
(Fig. 4a), and 45.5 ± 8, 45.3 ± 10, 30.8 ± 6 and 36.5 ± 6 touches with
both forelimbs at the same time, respectively (Fig. 4c). The number
of touches with only the ipsilateral forelimb and both forelimbs didFig. 4. Changes in forelimb asymmetry evaluated by cylinder test. Number of
forelimb touches to the surface of a cylinder with the rats’ ipsilateral (a),
contralateral (b) and both forelimbs (c) was counted. Data are expressed as
mean ± standard error of means (SEM). Statistical analyses were performed by one
way ANOVA followed by post hoc Tukey test. ⁄p < 0.05 and ⁄⁄p < 0.001 vs. sham
group; #p < 0.05 and ##p < 0.001 vs. L-ascorbic acid + PA group; and ap < 0.05 vs.
6-OHDA + sucrose group.not differ significantly among groups. On the other hand, compared
to sham group (7.36 ± 0.5), number of contralateral touches was
reduced significantly in 6-OHDA + Sucrose (1.8 ± 0.3; p < 0.001)
group while it was increased significantly in 6-OHDA + PA group
to 4 ± 0.8 (Fig. 4b).
Number of adjusting steps that the rats made did not differ sig-
nificantly among groups when rats were moved sideways on their
ipsilateral forelimb both in the ipsilateral and contralateral direc-
tions (Fig. 5a, b). On the contrary, number of adjusting steps was
reduced significantly in rats in the 6-OHDA + Sucrose group when
rats were moved sideways on their contralateral forelimb in the
ipsilateral (9.7 ± 1; p < 0.05) (Fig. 5c) and contralateral (3.5 ± 0.2;
p < 0.001) (Fig. 5d) directions compared with those in Sham group
(14.4 ± 0.4 in the ipsilateral and 10.4 ± 0.5 in the contralateral
direction). Compared with the 6-OHDA + Sucrose group, number
of contralateral touches tended to increase (11.2 ± 1) and did sig-
nificantly increase (6.2 ± 0.1; p < 0.05) in rats in the 6-OHDA + PA
group when rats in this group were moved sideways on their
contralateral forelimb in the ipsilateral (Fig. 5c) and contralateral
(Fig. 5d) direction, respectively.
Rotational behavior was tested initially in 6-OHDA-lesioned
rats in order to randomize rats to 6-OHDA + Sucrose and
6-OHDA + PA groups by ensuring similar number of ipsilateral
rotations (275 ± 11 and 275 ± 6, respectively) (Fig. 6a). Six weeks
after treatment, rats in 6-OHDA + Sucrose group displayed
almost identical number of ipsilateral rotations (273 ± 7) to that
observed before treatment onset while, on the contrary, number
of ipsilateral rotations were reduced significantly to 226 ± 2
(p < 0.001) in rats in the 6-OHDA + PA group after 6 weeks of
treatment (Fig. 6b).
3.4. PA nanofibers support tissue integrity and enhance cell migration
towards striatum
In order to monitor morphology of striatum, H&E staining was
carried out on brain sections taken from the rat brains at the end
of 6 weeks. H&E staining revealed that there was tissue loss due
to injection of 6-OHDA in 6-OHDA + Sucrose sections. Entry of
the cannula can be observed clearly and there was almost no cell
accumulation towards the damaged area. In contrast, PA injection
to the striatum provided better tissue integrity compared to
sucrose control. The gel was degraded at the end of 6 weeks, and
cells accumulated towards the injury site and covered this region
(Fig. 7). This result shows that the PA gel helps to maintain tissue
integrity in 6-OHDA injected striata. For characterization of cells
within the injury site, immunohistochemistry against Iba-1 was
performed, and cells that accumulated towards the injection site
in gel in 6-OHDA + PA groups were characterized as microglia
when staining positively for Iba-1 (Fig. 8).
3.5. PA nanofibers enhance striatal dopamine content
Intrastriatal 6-OHDA lesioning reduced the dopamine content
in the ipsilateral striatum from 0.94 ± 0.05 pmol/lg protein in
Sham group to 0.44 ± 0.02 pmol/lg protein (p < 0.001) in
6-OHDA + Sucrose group (Fig. 9). PA treatment enhanced this
reduced dopamine content significantly to 0.75 ± 0.01 pmol/lg
protein (p < 0.05) (Fig. 9). Dopamine content of ipsilateral striatum
did not differ in L-Ascorbic Acid + PA group (0.92 ± 0.05 pmol/lg
protein) compared with that in Sham group.
3.6. PA nanofibers enhance TH levels and TH immunoreactivity
Similarly to dopamine levels, TH levels were reduced signifi-
cantly in rats in 6-OHDA + Sucrose group by 79% (p < 0.001)
compared with the Sham group (Fig. 10A). The fall in striatal
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group (by 49%; p < 0.001) compared with Sham. On the other
hand, TH levels were significantly greater in 6-OHDA-lesioned
rats treated with PA compared with those receiving Sucrose
(p < 0.05) (Fig. 10A).
Immunohistochemistry against TH also showed that TH-
immunoreactivity almost disappeared in striatal sections, and
6-OHDA injection caused progressive dopaminergic cell loss in
6-OHDA + Sucrose group both in injury site and around this region.
However, this progressive cell loss was inhibited by PA gel in
6-OHDA + PA group. (Fig. 10B).Fig. 5. Changes in forelimb akinesia evaluated by stepping test. Number of adjusting ste
touching the table at a speed of 100 cm/5 s first in the forehand and then in the backha
ipsilateral forelimb towards ipsilateral direction (a), ipsilateral forelimb towards cont
contralateral forelimb towards contralateral direction (d). Data were expressed as mean
analyses were performed by one way ANOVA followed by post hoc Tukey test. ⁄⁄p < 0.0
OHDA + Sucrose group.
Fig. 6. Changes in rotational behavior evaluated by rotameter. Rats were injected intrape
and 45 min were recorded using an automated Rotameter system. Initial behavioral task
established and the data were used to randomize the 6-OHDA-lesioned rats into two
nanofibers (b). Data are expressed as mean ± SEM. Statistical analyses were performed b3.7. PA nanofibers reduce apoptosis
We investigated the extent of apoptosis by analyzing cleaved-
Caspase-3 levels in the lesioned striatum. Compared with sham
group, levels of cleaved-Caspase-3 almost doubled in rats with 6-
OHDA lesion which received Sucrose intrastriatally (196 ± 9%;
p < 0.001) while the increase in cleaved-Caspase-3 was less pro-
nounced in parkinsonian rats which received PA (156 ± 8%;
p < 0.001) (Fig. 11). Strikingly, the reduction of cleaved-Caspase-3
levels in PA group was significant compared to Sucrose group
(p < 0.001).ps that the rats made were counted when rats were moved sideways with one paw
nd direction. Figure shows mean number of adjusting steps made by the rat on its
ralateral direction (b), contralateral forelimb towards ipsilateral direction (c) and
± SEM of three tests performed with 30 min intervals on the same day. Statistical
01 vs. Sham group; ##p < 0.001 vs. L-Ascorbic Acid + PA group; and ap < 0.05 vs. 6-
ritoneally (i.p.) with d-amphetamine (5 mg/kg), and ipsilateral rotations between 15
(a) was performed in order to ensure that the unilateral striatal 6-OHDA lesion was
treatment groups while the test was repeated 6 weeks after administration of PA
y Student’s t test. ⁄⁄p < 0.05 vs. 6-OHDA + Sucrose group.
Fig. 7. H&E staining of striata of rat brain sections at postoperative week 6. The sections of 6-OHDA + PA group were compared with that of sham, L-Ascorbic Acid + PA and 6-
OHDA + Sucrose groups. Images were taken with 100X (Scale bars 200 lm in length) and 200X magnifications (Scale bars 100 lm in length).
Fig. 8. Immunohistochemistry against Iba-1 protein for rat brain sections at postoperative week 6. The sections of 6-OHDA + PA group were compared with that of Sham, L-
Ascorbic acid + PA and 6-OHDA + Sucrose groups. Images were taken with 100X (Scale bars 200 lm in length) and 200X magnifications (Scale bars 100 lm in length).
Fig. 9. Levels of dopamine in lesioned striatum. Data are expressed as mean ± SEM.
Statistical analyses were performed by one way ANOVA followed by post hoc Tukey
test. ⁄p < 0.05 and ⁄⁄p < 0.001 vs. Sham group; #p < 0.05 and ##p < 0.001 vs. L-
Ascorbic Acid + PA group; and ap < 0.05 vs. 6-OHDA + Sucrose group.
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PD is a chronic and progressive disorder affecting millions of
people worldwide, and is manifested by motor symptoms such
as tremor, bradykinesia, rigidity and postural instability. Symp-
toms arise initially as a consequence of degeneration of dopamin-ergic nigrostriatal neurons and reduction in striatal dopamine
levels. Etiopathogenesis of PD includes various factors such as
alpha-synuclein dysfunction, ubiquitin-proteasome system, lyso-
somal autophagy, endoplasmic reticulum stress, mitochondrial
dysfunction, oxidative stress and calcium dysregulation [37]. Sev-
eral alternative treatments are being tested both experimentally
and clinically which target one or more of these ethiopathogenetic
factors. Recently, enhanced apoptotic cell death has been sug-
gested as an underlying mechanism for progressive striatal neu-
rodegeneration [4–7].
Although current treatment approaches, including the gold
standard L-Dopa, provide benefit in particularly early stages of
the disease, these approaches have been used just to relieve the
symptoms and they become inadequate in the late stages. There
are no therapies for PD to slow down the degeneration process in
the brain and recover the lost function yet. Therefore, recent
advances in regenerative medicine and tissue engineering would
be a good therapeutic approach for neurodegenerative diseases like
PD. In this study, we utilized a bioactive peptide nanofiber system
for enhancing neuroprotection against 6-OHDA-induced cytotoxic-
ity both in vitro and in vivo. These nanofibers are formed through
the self-assembly of short bioactive PA molecules (LN-PA and
GAG-PA) that were designed to mimic both laminin and heparan
sulfate, since they can induce neurite outgrowth [29]. Heparin
was also shown to stabilize laminin networks which lead to better
neuritogenesis through heparin–laminin complexes [38].
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to enhance the efficacy of the PA nanofibers used in this study.
PA scaffolds used in this study are similar to ECM of neural tissues
in terms of physical appearance of fibrous networks. When design-
ing a scaffold for nervous tissue, the mechanical characteristics of
the scaffold should be similar to that of brain tissue, which is about
1 kPa [39]. Rheological measurements confirmed that all PA com-
binations formed gels and displayed similar properties to nervous
tissue.
We observed that viability of the cells on all surfaces was com-
parable at the end of 24 h, which emphasizes the biocompatibility
of all PA nanofiber combinations for SH-SY5Y cells, which are used
as in vitro cell model of dopaminergic neurons in PD. When we
treated the cells with 6-OHDA for 24 h, the highest viability was
observed in SH-SY5Y cells seeded on LN-PA/GAG-PA combination,
which was significantly different from other surfaces. For detailed
analysis of neuroprotection of LN-PA/GAG-PA combination, we
checked apoptosis using Annexin V FITC and propidium iodide
assay, which indicates specific morphologic features of apoptosisFig. 10. Levels of Tyrosine Hydroxylase (TH) analyzed byWestern blot (A) and immunohi
expressed as mean ± SEM. Statistical analyses were performed by one way ANOVA followe
+ PA group; and ap < 0.05 vs. 6-OHDA + Sucrose group. In immunohistochemical analyses
immunostaining was detected in the lesion area in 6-OHDA + PA group at an extent simila
(Scale bars 200 lm in length) and 200X magnifications (Scale bars 100 lm in length).to categorize type of cell death. Flow cytometry analyses showed
that live cells were significantly highest in LN-PA/GAG-PA combi-
nation, which is compatible with calcein/ethidium homodimer
live-dead assay results. In contrast, late apoptotic cells were lowest
in this group, which was significantly different from other PA com-
binations and TCP. These results make LN-PA/GAG-PA combination
the best option for further in vivo studies.
The 6-OHDA model of nigral injury has been utilized for dec-
ades as a clinical experimental model of PD [40]. Intrastriatal injec-
tion of 6-OHDA leads to retrograde and progressive degeneration,
thus providing a useful approach to study neuroprotective and
neuroregenerative effects of experimental studies. We used this
model for in vivo studies and injury was verified with
amphetamine-induced rotational test. After injury, we injected
bioactive gel as a therapeutic agent to prevent toxic effect of 6-
OHDA. It was observed that the peptide gel disintegrated and pro-
vided cell accumulation towards the injury site, which was appar-
ent 21 days after the PA gel injections (Fig. S3). These cells were
characterized as microglia through immunohistochemical analysisstochemistry (B) in lesioned striatum. Data obtained inWestern blot analyses (A) are
d by post hoc Tukey test. ⁄⁄p < 0.001 vs. Sham group; ##p < 0.001 vs. L-Ascorbic Acid
, no staining against TH was observed in 6-OHDA + Sucrose group, while TH protein
r with that observed in L-Ascorbic Acid + PA group (B). Images were taken with 100X
Fig. 11. Levels of cleaved-Caspase-3 analyzed by Western blot. Data were
expressed as mean ± SEM. Statistical analyses were performed by one way ANOVA
followed by post hoc Tukey test. ⁄⁄p < 0.001 vs. Sham group; ##p < 0.001 vs. L-
Ascorbic Acid + PA group; and aap < 0.001 vs. 6-OHDA + Sucrose group.
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in regulation of microglial function. Microglial activation occurs
in central nervous system as a result of several pathological situa-
tions including inflammation and degeneration [41,42]. Microglia
can serve for removal of deleterious debris by phagocytic activity
after brain injury or neurodegeneration and contribute to neuro-
protection by releasing neurotrophic factors [43,44]. In addition,
properly-activated microglia have been shown to restrict the lesion
area and provide protection in an experimental model of PD [45].
Therefore, we suggest that PA nanofibers behaved as a scaffold
mimicking the ECM which enabled cell accumulation to alleviate
the extent of the injury created by 6-OHDA injection.
Besides recruiting microglia, another mechanism by which PA
nanofibers provide protection in the 6-OHDA rat model of PD
might be represented by their anti-apoptotic activity, as shown
in our study by reduction of the enhanced cleaved-Caspase-3 levels
in vehicle (Sucrose) group. In good accord, a recent study showed
that silencing of Caspase-3 by RNA interference reduced striatal
dopaminergic cell loss and increased locomotor activity in a rat
model of PD [8], suggesting a role for apoptosis in the pathogenesis
of PD. The reduction in cleaved-Caspase-3 levels observed in our
study therefore contributes to our understanding of how PA nano-
fibers provide protection in a rat model of PD, as has been shown
previously for IKVAV-carrying epitopes in spinal cord injury [28].
The beneficial effect of PAs in the current model was repre-
sented biochemically by increased dopamine and TH content of
the 6-OHDA-lesioned striatum. In addition, PA treatment also
improved behavioral consequences of the experimental parkinso-
nian lesion by reducing forelimb asymmetry and akinesia as well
as decreasing the number of ipsilateral rotations induced by
systemic d-amphetamine administration. The ameliorations in bio-
chemical and behavioral parameters observed in the present study
are probably associated with anti-apoptotic and microglia-
recruiting activities of PA nanofibers which resulted in restriction
of the 6-OHDA lesion and enabled survival of a greater number
of dopaminergic neurons, as has been shown in in vitro
experiments.
Overall, striatal microinjection of heparan sulfate and laminin
mimetic PA nanofibers reduced striatal pathology and improved
behavioral consequences in a rat model of PD by providing cell
recruitment, preventing progressive cell loss and reducing apopto-sis. This is the first study that reports beneficial effects of bioactive
PA nanofibers in the treatment of neurodegenerative disorders and
these PA nanofibers may be used as a promising new strategy for
the treatment of PD.
5. Conclusion
Herein we utilized a bioactive PA nanofiber gel system for thera-
peutic effect in both for SH-SY5Y cell culture and experimental PD
model. In vitro results revealed that laminin-derived peptide signals
along with heparan-sulfate-mimicking epitope were found to pro-
vide better viability through decreasing the apoptosis after 6-
OHDA treatment. Furthermore, in vivo results showed that this scaf-
fold is effective on reducing striatal injury and enhancing functional
recovery after unilateral striatal injection of 6-OHDA. Also, histolog-
ical analyses demonstrated that PA gel helped to maintain tissue
integrity in 6-OHDA injected striata and prevented progressive
dopaminergic cell loss around the damaged area. Overall, incorpora-
tion of heparan sulfate and laminin mimetic epitopes into PA nano-
fiber system decreased the toxic effect of 6-OHDA and provided
better functional outcomes. This is the first study that reports the
protective effects of PA nanofibers in a neurodegenerative disease
model, which makes this system a promising therapeutic approach
against degeneration in PD, but there still is a need for further stud-
ies to see the effects of these PA nanofibers on genetic model before
the clinical trials since genetic models may better simulate the
mechanisms underlying the genetic forms of PD. In addition, further
studies on reducing the invasivenessof this techniquewouldbeben-
eficial prior to testing it in clinical settings.
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